New drug trial aims to ease sudden heart failure in hospitalized patients
NCT ID NCT06556810
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether the drug atibuclimab (IC14) is safe and helpful for adults hospitalized with sudden worsening heart failure. Ten participants receive one IV dose of the drug and are monitored for side effects, drug levels, and heart failure markers. The goal is to gather initial safety and effectiveness data, with no placebo group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE DECOMPENSATED HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
Virginia Commonwealth University
Richmond, Virginia, 23298, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Are heart failure patients taking their meds? a urine test at the ER aims to find out
- Can common heart drugs stay safe during a crisis? a trial investigates
- Heart failure fluid removal device trial halted early
- Massive new registry aims to unlock secrets of deadly heart shock
- Heart failure study aims to tailor treatments using biomarkers
- New device automates fluid removal in heart failure – could it be a game changer?